Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company focused on neurological therapeutics, announced it will present and host one-on-one meetings with investors at the Sidoti Micro-Cap Virtual Investor Conference, scheduled for May 20-21, 2026. The company's presentation is set for 3:15 p.m. ET on May 21, 2026, with additional virtual one-on-one meetings throughout the event.
The announcement provides an opportunity for investors to learn more about Oragenics' lead candidate, ONP-002, which is being developed as a potential first-in-class treatment for concussion and mild traumatic brain injury. The company is preparing to commence clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. Oragenics' proprietary intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders.
Participation in the Sidoti conference is significant for Oragenics as it seeks to raise visibility among micro-cap investors and potentially secure funding to advance its pipeline. The company's focus on neurological therapeutics addresses a substantial unmet medical need, as traumatic brain injury affects millions worldwide each year, and current treatment options are limited.
For investors, the conference represents a chance to engage directly with Oragenics' management and gain insights into the company's clinical development plans and regulatory strategy. The virtual format allows broader access, enabling investors from various locations to participate without travel costs.
Oragenics is committed to developing innovative therapies for neurological conditions. More information is available at oragenics.com. The full press release can be viewed at https://ibn.fm/MLd0Y.
